Hyeon-Su Im

748 total citations
25 papers, 268 citations indexed

About

Hyeon-Su Im is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hyeon-Su Im has authored 25 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hyeon-Su Im's work include Pancreatic and Hepatic Oncology Research (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Palliative Care and End-of-Life Issues (5 papers). Hyeon-Su Im is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Palliative Care and End-of-Life Issues (5 papers). Hyeon-Su Im collaborates with scholars based in South Korea and Canada. Hyeon-Su Im's co-authors include Jaekyung Cheon, Sook Ryun Park, Baek‐Yeol Ryoo, Choong‐kun Lee, Hye Jin Choi, Eun‐Hae Cho, Myoung Joo Kang, Hong Jae Chon, JiHoon Kang and Beodeul Kang and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

Hyeon-Su Im

22 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hyeon-Su Im South Korea	9	127	109	86	65	42	25	268
Paola Bertocchi Italy	12	188 1.5×	45 0.4×	77 0.9×	61 0.9×	33 0.8×	25	269
Zhonglian He China	9	75 0.6×	100 0.9×	178 2.1×	76 1.2×	16 0.4×	17	320
S. Pugh United Kingdom	14	260 2.0×	144 1.3×	98 1.1×	136 2.1×	88 2.1×	36	506
Amanda R. Kahl United States	10	167 1.3×	79 0.7×	45 0.5×	27 0.4×	20 0.5×	33	291
Maurizio Leoni Italy	11	168 1.3×	43 0.4×	95 1.1×	35 0.5×	35 0.8×	21	290
Brooke Vuong United States	11	365 2.9×	237 2.2×	166 1.9×	86 1.3×	52 1.2×	38	555
Mihir M. Shah United States	10	161 1.3×	168 1.5×	161 1.9×	38 0.6×	22 0.5×	68	369
Maarten G.J. Thomeer Netherlands	11	135 1.1×	137 1.3×	97 1.1×	20 0.3×	19 0.5×	21	301
Leila Bengrine France	9	168 1.3×	90 0.8×	71 0.8×	21 0.3×	18 0.4×	24	232
Mary M. Mullen United States	11	136 1.1×	58 0.5×	22 0.3×	32 0.5×	72 1.7×	29	274

Countries citing papers authored by Hyeon-Su Im

Since Specialization

Citations

This map shows the geographic impact of Hyeon-Su Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyeon-Su Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyeon-Su Im more than expected).

Fields of papers citing papers by Hyeon-Su Im

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyeon-Su Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyeon-Su Im. The network helps show where Hyeon-Su Im may publish in the future.

Co-authorship network of co-authors of Hyeon-Su Im

This figure shows the co-authorship network connecting the top 25 collaborators of Hyeon-Su Im. A scholar is included among the top collaborators of Hyeon-Su Im based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyeon-Su Im. Hyeon-Su Im is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Hong-Sik, Soo Ick Cho, Hong Jae Chon, et al.. (2025). Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin. JCO Precision Oncology. 9(9). e2500510–e2500510.

Kim, Hyeyeong, et al.. (2024). Effectiveness of self-reported management program of cancer patients. Digital Health. 10. 599896802–599896802. 1 indexed citations

Kim, Hyeyeong, Hyeon-Su Im, Jae‐Cheol Jo, et al.. (2023). Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic. Psychiatry Investigation. 20(12). 1204–1210. 2 indexed citations

Im, Hyeon-Su, Insook Lee, Jong Lee, et al.. (2023). Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study. BMC Medical Ethics. 24(1). 18–18.

Kim, Hyeyeong, et al.. (2023). Development and pilot study of “Smart Cancer Care”: a platform for managing side effects of chemotherapy. BMC Health Services Research. 23(1). 922–922. 6 indexed citations

Noh, Eui‐Kyu, Yoo Jin Lee, Youjin Kim, et al.. (2022). The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation. BMC Cancer. 22(1). 997–997. 2 indexed citations

Lee, Choong‐kun, Hong Jae Chon, Jaekyung Cheon, et al.. (2022). Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). The Lancet. Gastroenterology & hepatology. 8(1). 56–65. 75 indexed citations

Koh, Su‐Jin, Kyung‐Ah Kang, Hyeyeong Kim, et al.. (2022). Perceptions of the meaning of life among Korean patients with advanced cancer: A mixed-methods study. Palliative & Supportive Care. 21(4). 658–669. 9 indexed citations

Pyo, Jeehee, Minsu Ock, Mina Lee, et al.. (2021). Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study. BMC Palliative Care. 20(1). 58–58. 8 indexed citations

10.

Kim, Donghyun, et al.. (2021). Development of the Rule-based Smart Tourism Chatbot using Neo4J graph database. 13(2). 179–186. 5 indexed citations

11.

Cheon, Jaekyung, Jae Ho Jeong, Hyeon-Su Im, et al.. (2021). Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Therapeutic Advances in Medical Oncology. 13. 4277415085–4277415085. 11 indexed citations

12.

Kang, Beodeul, Hong Jae Chon, Hyeon-Su Im, et al.. (2021). Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open. 6(2). 100049–100049. 24 indexed citations

13.

Jeong, Hyehyun, Hyeon-Su Im, Wanlim Kim, et al.. (2021). Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea—A Sarcoma-Specific, Institutional Registry-Based Analysis. Cancer Management and Research. Volume 13. 8795–8802. 3 indexed citations

14.

Kim, Hyung‐Don, Hyeon-Su Im, Jwa Hoon Kim, et al.. (2021). Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. Cancer Research and Treatment. 53(4). 1166–1173. 4 indexed citations

15.

Kim, Hyeyeong, Hyeon-Su Im, Young Joo Min, et al.. (2021). Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. BMC Palliative Care. 20(1). 63–63. 11 indexed citations

16.

Lee, Sung Hwan, Jaekyung Cheon, Seo-Young Lee, et al.. (2021). ARID1A mutation to predict disease progression during first-line chemotherapy in biliary tract cancer patients.. Journal of Clinical Oncology. 39(15_suppl). 4105–4105. 1 indexed citations

17.

Im, Hyeon-Su, et al.. (2020). Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. Current Problems in Cancer. 45(3). 100685–100685. 9 indexed citations

18.

Kim, Jwa Hoon, Seyoung Seo, Kyu‐pyo Kim, et al.. (2020). Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. In Vivo. 34(2). 829–837. 14 indexed citations

19.

Kong, Sun‐Young, Hyeon-Su Im, Hwa Jung Kim, et al.. (2019). Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer. 19(1). 292–292. 56 indexed citations

20.

Yoo, Changhoon, Hyeon-Su Im, Kyu‐pyo Kim, et al.. (2019). Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. Journal of Clinical Oncology. 37(4_suppl). 344–344. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact